Home Other Building Blocks N-Cyclohexyl-N-methyl-4-((2-oxo-1,2-dihydroquinolin-6-yl)oxy)butanamide

N-Cyclohexyl-N-methyl-4-((2-oxo-1,2-dihydroquinolin-6-yl)oxy)butanamide

CAS No.:
68550-75-4
Catalog Number:
AG0034LX
Molecular Formula:
C20H26N2O3
Molecular Weight:
342.4320
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
250mg
95%
In Stock USA
United States
$375
- +
Product Description
Catalog Number:
AG0034LX
Chemical Name:
N-Cyclohexyl-N-methyl-4-((2-oxo-1,2-dihydroquinolin-6-yl)oxy)butanamide
CAS Number:
68550-75-4
Molecular Formula:
C20H26N2O3
Molecular Weight:
342.4320
MDL Number:
MFCD00673958
IUPAC Name:
N-cyclohexyl-N-methyl-4-[(2-oxo-1H-quinolin-6-yl)oxy]butanamide
InChI:
InChI=1S/C20H26N2O3/c1-22(16-6-3-2-4-7-16)20(24)8-5-13-25-17-10-11-18-15(14-17)9-12-19(23)21-18/h9-12,14,16H,2-8,13H2,1H3,(H,21,23)
InChI Key:
UIAYVIIHMORPSJ-UHFFFAOYSA-N
SMILES:
O=C(N(C1CCCCC1)C)CCCOc1ccc2c(c1)ccc(=O)[nH]2
UNII:
45S5605Q18
Properties
Complexity:
499  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
342.194g/mol
Formal Charge:
0
Heavy Atom Count:
25  
Hydrogen Bond Acceptor Count:
3  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
342.439g/mol
Monoisotopic Mass:
342.194g/mol
Rotatable Bond Count:
6  
Topological Polar Surface Area:
58.6A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2.9  
Literature
Title Journal
Effects of lipoic acid on lipolysis in 3T3-L1 adipocytes. Journal of lipid research 20121101
Pharmacologic agents elevating cAMP prevent arginase II expression and proliferation of pulmonary artery smooth muscle cells. American journal of respiratory cell and molecular biology 20120801
Gap junction-mediated communications regulate chromatin remodeling during bovine oocyte growth and differentiation through cAMP-dependent mechanism(s). Biology of reproduction 20111201
Acylated and unacylated ghrelin attenuate isoproterenol-induced lipolysis in isolated rat visceral adipocytes through activation of phosphoinositide 3-kinase γ and phosphodiesterase 3B. Biochimica et biophysica acta 20110601
Neurite outgrowth mediated by translation elongation factor eEF1A1: a target for antiplatelet agent cilostazol. PloS one 20110101
Simulated physiological oocyte maturation (SPOM): a novel in vitro maturation system that substantially improves embryo yield and pregnancy outcomes. Human reproduction (Oxford, England) 20101201
Anagrelide represses GATA-1 and FOG-1 expression without interfering with thrombopoietin receptor signal transduction. Journal of thrombosis and haemostasis : JTH 20101001
Function of cardiac beta1- and beta2-adrenoceptors of newborn piglets: role of phosphodiesterases PDE3 and PDE4. European journal of pharmacology 20100725
A role of phosphodiesterase-3B pathway in mediating leptin action on proopiomelanocortin and neurotensin neurons in the hypothalamus. Neuroscience letters 20100719
PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation. Basic research in cardiology 20100501
Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals. Circulation research 20091009
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. Nature chemical biology 20091001
Design, synthesis and pharmacological evaluation of 6-hydroxy-4-methylquinolin-2(1H)-one derivatives as inotropic agents. Journal of enzyme inhibition and medicinal chemistry 20090801
Effects of the cAMP-elevating agents cilostamide, cilostazol and forskolin on the phosphorylation of Akt and GSK-3beta in platelets. Thrombosis and haemostasis 20090801
Cilostamide produces hyperpolarization associated with K(ATP) channel activation, but does not augment endothelium-derived hyperpolarization in rat mesenteric arteries. Clinical and experimental pharmacology & physiology 20090701
Phosphodiesterases PDE3 and PDE4 jointly control the inotropic effects but not chronotropic effects of (-)-CGP12177 despite PDE4-evoked sinoatrial bradycardia in rat atrium. Naunyn-Schmiedeberg's archives of pharmacology 20090401
Inotropy and L-type Ca2+ current, activated by beta1- and beta2-adrenoceptors, are differently controlled by phosphodiesterases 3 and 4 in rat heart. British journal of pharmacology 20090101
Ontogenic changes of the control by phosphodiesterase-3 and -4 of 5-HT responses in porcine heart and relevance to human atrial 5-HT(4) receptors. British journal of pharmacology 20090101
Phosphodiesterase 3 is present in rabbit and human erythrocytes and its inhibition potentiates iloprost-induced increases in cAMP. American journal of physiology. Heart and circulatory physiology 20080801
Effect of temporary nuclear arrest by phosphodiesterase 3-inhibitor on morphological and functional aspects of in vitro matured mouse oocytes. Molecular reproduction and development 20080601
Spatiotemporal dynamics of beta-adrenergic cAMP signals and L-type Ca2+ channel regulation in adult rat ventricular myocytes: role of phosphodiesterases. Circulation research 20080509
Effects of cilostamide and forskolin on the meiotic resumption and embryonic development of immature human oocytes. Human reproduction (Oxford, England) 20080301
Phosphodiesterase-4 blunts inotropism and arrhythmias but not sinoatrial tachycardia of (-)-adrenaline mediated through mouse cardiac beta(1)-adrenoceptors. British journal of pharmacology 20080201
Numerous distinct PKA-, or EPAC-based, signalling complexes allow selective phosphodiesterase 3 and phosphodiesterase 4 coordination of cell adhesion. Cellular signalling 20071201
The effects of both noradrenaline and CGP12177, mediated through human beta1 -adrenoceptors, are reduced by PDE3 in human atrium but PDE4 in CHO cells. Naunyn-Schmiedeberg's archives of pharmacology 20070401
Cilostamide potentiates more the positive inotropic effects of (-)-adrenaline through beta(2)-adrenoceptors than the effects of (-)-noradrenaline through beta (1)-adrenoceptors in human atrial myocardium. Naunyn-Schmiedeberg's archives of pharmacology 20061201
Phosphodiesterase PDE3 blunts the positive inotropic and cyclic AMP enhancing effects of CGP12177 but not of noradrenaline in rat ventricle. British journal of pharmacology 20060101
New insight into the role of phosphodiesterase 3A in porcine oocyte maturation. BMC developmental biology 20060101
Effects of long-term in vitro exposure to phosphodiesterase type-3 inhibitors on follicle and oocyte development. Reproduction (Cambridge, England) 20050801
The phosphodiesterase 3 inhibitor cilostamide enhances inotropic responses to glucagon but not to dobutamine in rat ventricular myocardium. European journal of pharmacology 20050411
Fundamental significance of specific phosphodiesterases in the control of spontaneous meiotic resumption in porcine oocytes. Molecular reproduction and development 20050301
Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. Molecular pharmacology 20050101
Mouse oocyte meiotic resumption and polar body extrusion in vitro are differentially influenced by FSH, epidermal growth factor and meiosis-activating sterol. Human reproduction (Oxford, England) 20041201
The action mechanism of zinc(II) complexes with insulinomimetic activity in rat adipocytes. Life sciences 20040625
Identification of purine inhibitors of phosphodiesterase 7 (PDE7). Bioorganic & medicinal chemistry letters 20040607
Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in diet-induced obesity. The Journal of biological chemistry 20040521
Augmentation of lipolysis in adipocytes from fed rats, but not from starved rats, by inhibition of rolipram-sensitive phosphodiesterase 4. Archives of biochemistry and biophysics 20040501
Benzyl vinylogous amide substituted aryldihydropyridazinones and aryldimethylpyrazolones as potent and selective PDE3B inhibitors. Bioorganic & medicinal chemistry letters 20031117
Synthesis and pharmacological characterization of functionalized 2-pyridones structurally related to the cardiotonic agent milrinone. Bioorganic & medicinal chemistry 20031103
The role of tryptophan 1072 in human PDE3B inhibitor binding. Biochemical and biophysical research communications 20030808
Phosphodiesterase 3 activity is reduced in dog lung following pacing-induced heart failure. American journal of physiology. Lung cellular and molecular physiology 20030501
Phosphodiesterase 3 inhibitors selectively block the spontaneous resumption of meiosis by macaque oocytes in vitro. Human reproduction (Oxford, England) 20020801
Changes in phosphodiesterase activity in the developing rat submandibular gland. Archives of oral biology 20020801
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. The Journal of biological chemistry 20020419
Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation. Developmental biology 20020415
Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR:LA-cp rat aortic vascular smooth muscle cells: implications for diabetes-associated cardiovascular disease. Diabetes 20020401
Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research 20020201
Mechanism of intracellular calcium ([Ca2+]i) inhibition of lipolysis in human adipocytes. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20011101
Inhibitors of phosphodiesterase isoforms III or IV suppress islet-cell nitric oxide production. Laboratory investigation; a journal of technical methods and pathology 20010801
Cyclic GMP regulation of the L-type Ca(2+) channel current in human atrial myocytes. The Journal of physiology 20010601
Characterization of an in vivo hormonally regulated phosphodiesterase 3 (PDE3) associated with a liver Golgi-endosomal fraction. Archives of biochemistry and biophysics 20010301
Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochemical pharmacology 20000215
Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide. Journal of medicinal chemistry 19870201
Properties